Program
PF-07328948
Also written as “Low Dose PF-07328948”, “Medium Dose PF-07328948” and “High Dose PF-07328948”.
In Pfizer's pipeline, Branched chain ketoacid dehydrogenase kinase (BDK) inhibitor
. Its studies are mostly in Heart Failure · Renal Insufficiency, led by Pfizer.
Furthest: phase 2, since May 19, 20258 company-led studies, 3 open or runningNext primary completion: Feb 23, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 83 open or running | phase 2since May 19, 2025 | Oct 13, 2022 | Feb 23, 2027phase 1 · NCT07269301 |
- Named in Pfizer’s own pipeline as
PF-07328948
, phase 2, as of Nov 3, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 13, 2022First study: phase 1 study in HealthyFirst studyNCT05654181 · 20 enrolled · United States
- Mar 29, 2023Phase 1 study in HealthyNCT05807490 · 86 enrolled · United States, Belgium
- Feb 14, 2025Phase 1 study in Healthy AdultsNCT06837259 · 26 enrolled · Belgium
- May 19, 2025Phase 2 study in Heart FailureNCT06991257 · 620 planned · United States, Argentina, Brazil and more
- Nov 25, 2025Phase 1 study in Hepatic ImpairmentNCT07269301 · 26 planned · United States
- Dec 18, 2025Phase 1 study in Renal InsufficiencyNCT07315360 · 28 planned · United States
- Mar 3, 20262 phase 1 studiesNCT07455240, NCT07508228
- Oct 23, 2026Primary completion moved from 2027-11-16 to 2028-05-08Date moved laterphase 2 · +6 months · NCT06991257
Ahead
- Feb 23, 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07269301
- Mar 13, 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07315360
- May 8, 2028Primary completion: phase 2 study in Heart FailureNCT06991257
TargetBeta
“Branched chain ketoacid dehydrogenase kinase (BDK) inhibitor”the company's pipeline, read by Claude · source
“A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN ORAL BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE INHIBITOR, PF-07328948, IN ADULTS WITH HEART FAILURE (BRANCH-HF)”study text, read by Claude · the study
Other programs on BCKDK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| IVPF-07328948 | Pfizer | phase 1 | 1 |
| ORALPF-07328948 | Pfizer | phase 1 | 1 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07508228Healthy · United States | 1 | Completed | Jul 10, 2026 | 8 |
| NCT07455240Healthy Participant · China | 1 | Completed | Apr 15, 2026 | 10 |
| NCT07315360Renal Insufficiency · United States | 1 | Recruiting | Mar 13, 2027 | 28 |
| NCT07269301Hepatic Impairment · United States | 1 | Recruiting | Feb 23, 2027 | 26 |
| NCT06991257Heart Failure · United States, Argentina, Brazil and more | 2 | Recruiting | May 8, 2028 | 620 |
| NCT06837259Healthy Adults · Belgium | 1 | Completed | Jun 11, 2025 | 26 |
| NCT05807490Healthy · United States, Belgium | 1 | Completed | Jul 10, 2024 | 86 |
| NCT05654181Healthy · United States | 1 | Completed | May 3, 2023 | 20 |
How it is read
Names in the registry
- “PF-07328948”, 17 entries
- “Low Dose PF-07328948”, 1 entry
- “Medium Dose PF-07328948”, 1 entry
- “High Dose PF-07328948”, 1 entry
- “Oral Unlabeled PF-07328948”, 1 entry
Conditions, from the studies’ own filings
- Heart Failure, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.